| Document |
Document Title |
|
WO/2024/077145A1 |
The present disclosure in various aspects and embodiments relates to cell compositions (and methods for making or using the same) comprising hematopoietic stem cells (HSCs) and/or hematopoietic stem progenitor cells (HSPCs), where the HS...
|
|
WO/2024/075676A1 |
The present invention pertains to an agent that is for treating or preventing cerebral palsy, that contains dental pulp stem cells, and that is to be administered to a subject having a symptom of cerebral palsy.
|
|
WO/2024/074709A1 |
The present invention relates to the field of synthetic evolution, and provides with a virus-assisted evolution platform for hyper-directed evolution of phenotypes in mammalian cells.
|
|
WO/2024/077116A1 |
A pharmaceutical composition for use in promoting bone/cartilage regeneration, includes a PEDF-derived short peptide (PDSP); and mesenchymal stem cells (MSCs). The PDSP is 14-39 amino acids long. The PDSP has the amino-acid sequence sele...
|
|
WO/2024/076121A1 |
The present invention relates to immune cells co-expressing IL-15 and a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain, and to a composition for preventing or treating cancer comprising same as a...
|
|
WO/2024/074142A1 |
Provided are codon-optimized GBA1polynucleotides that encode a GCase protein, with a portion of the coding sequence deviating from the wild-type. Additionally provided are expression constructs, vectors, viral particles, or compositions ...
|
|
WO/2023/215302A3 |
Methods of treating cancer in subjects in need thereof by administering a combination therapy including (a) a T cell expressing a T cell antigen coupler (TAC) polypeptide having (i) an antigen-binding domain that binds a target antigen, ...
|
|
WO/2024/076910A2 |
Organoid culture and image-processing methods and systems are described. Such methods and systems provide the ability for high-throughput characterization of a variety of phenotypes at single-organoid resolution.
|
|
WO/2024/007018A3 |
The present disclosure provides methods and compositions for stem cell differentiation. In some examples, the stem cell is a pluripotent stem cell (PSC). The PSC may comprise a nucleic acid comprising an open reading frame encoding one o...
|
|
WO/2024/075722A1 |
The present invention provides: a method for culturing adhesive cells using a microcarrier coated with a polymer that exhibits a lower critical temperature within a culture vessel, wherein the method is characterized by including the fol...
|
|
WO/2024/076605A1 |
Provided herein are multilineage cardiovascular organoids and methods of generating the same. In some aspects, provided herein is a system comprising a plurality of multilineage cardiovascular organoids derived from embryoid bodies. The ...
|
|
WO/2024/030970A3 |
Several embodiments of the methods and compositions disclosed herein relate to immune cells that are genetically edited, for example, using Crispr/Cas, to modulate, reduce or otherwise eliminate expression of one or more endogenous genes...
|
|
WO/2024/077140A1 |
In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specif...
|
|
WO/2024/077153A1 |
The present disclosure provides for efficient ex vivo processes for generating megakaryocytes and/or platelets from human induced pluripotent stem cells (iPSCs). Cells and platelets generated according to the disclosure in various embodi...
|
|
WO/2024/074540A2 |
The invention relates to a genetically engineered cell and compositions comprising said cell, wherein said cell is engineered to be especially sensitive towards two or more environmental factors, to enhance the biosafety profile of said ...
|
|
WO/2024/073845A1 |
The present application relates to methods for expanding hematopoietic stem cells (HSC) and/or hematopoietic progenitor cells (HPC) ex vivo and/or in vivo. The methods comprise culturing the HSCs and/or HPCs in the presence of a selectiv...
|
|
WO/2024/077174A1 |
The present disclosure provides methods of preparing immune cells, e.g., T cells and/or NK cells, comprising contacting the cells with programmable cell-signaling scaffolds in a medium comprising at least about 5 mM potassium ion and edi...
|
|
WO/2024/077274A1 |
Provided here are cell culture system with tunable stiffness comprising a biocompatible polydimethyl siloxane substrate and a polyelectrolyte multilayer. Also provided here are methods of making and using these systems as research and/or...
|
|
WO/2024/077270A1 |
Described herein are immunoresponsive cells engineered to express cytokines and chimeric receptors. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2024/044771A3 |
The present disclosure provides modified immune cells or precursors thereof comprising chimeric antigen receptors and surface-bound, biologically inert molecules. Also included are methods of preparing said modified immune cells and meth...
|
|
WO/2024/077295A2 |
The present disclosure provides methods, compositions, and systems for producing and using organoids comprising fibroblasts. The organoids can be generated and placed in a particular storage matrix which allows for sufficient conditions ...
|
|
WO/2024/075756A1 |
Provided is a method for producing a library containing gene-modified cells. This library is useful in the functional evaluation of a specific region of a genome and the introduction, etc., of various types of mutations (such as SNPs) to...
|
|
WO/2023/064925A8 |
Use of an autologous e.g., selected, renal cell therapeutic for improving kidney function of a human patient having diabetic chronic kidney disease is provided herein. The use of the therapeutic, administered in first and second injectio...
|
|
WO/2024/076758A1 |
Methods and composition for growth and maintenance of Oct3/4+ SOX2+ NANOG+ pluripotent stem cells (PSCs) or generation and maintenance of CD7+ CD75+ CD77+ CD 130+ F11R+ naive PSCs in cell culture comprise the use of a small molecule-base...
|
|
WO/2024/075803A1 |
The present invention addresses the problem of providing: a method for testing a cranial nerve disease including schizophrenia, or a method for testing the sensitivity to a cranial nerve disease; and a reagent and a kit for use in the te...
|
|
WO/2024/075941A1 |
The present invention relates to super absorbent polymer-based surface fixation technology for extracellular vesicles or cells and, more specifically, to a technology and applications thereof, the technology fixing, to the surface of a s...
|
|
WO/2024/077158A1 |
In various aspects and embodiments, the present disclosure provides methods for generating T cell populations for cell therapy, including T lymphocytes (T cells) and progenitor T cells. In various embodiments, the invention provides for ...
|
|
WO/2024/026199A3 |
Provided herein are inhibitory chimeric antigen receptor compositions and cells comprising such compositions. Also provided are methods of using inhibitory chimeric antigen receptors and cells.
|
|
WO/2024/076173A1 |
Disclosed are a composition for inducing differentiation of adipose-derived stem cells into dermal papilla cells, and a differentiation method using the composition. The composition for inducing differentiation and the differentiation me...
|
|
WO/2024/077255A1 |
Transgenic bioincubators are provided having an FAH transgene or endogenous FAH modified with an inducible promoter. The inducible promoter allows for control of the expression of FAH in the presence or absence of an inducer, for purpose...
|
|
WO/2024/076329A1 |
The invention relates to an exosome-based biocompatible implant obtained by spraying exosomes obtained from stem cells onto implant materials consisting of different materials. Said exosomes are attached to the implant material at a leve...
|
|
WO/2024/076507A1 |
Methods for improving parthenogenesis efficiency by DWT1 and BABY BOOM transcription factors in plants are provided. A rice embryo trigger transcription factor BABY BOOM1 can initiate embryogenesis when expressed in the unfertilized egg ...
|
|
WO/2024/050534A3 |
Hematopoietic stem progenitor cells (HSPCs) are multipotent, self-renewing, progenitor cells capable of generating every type of blood cell arising from both the lymphoid and myeloid lineages. Since many types of cancer, including leukem...
|
|
WO/2024/076182A1 |
The present invention relates to a medium composition for preparing a salivary gland organoid. Also, the present invention relates to: a method for preparing a salivary gland organoid, comprising a step of culturing salivary gland-derive...
|
|
WO/2024/074376A1 |
The present invention relates to a macrophage, genetically engineered to overexpress Interleukin-10 (IL-10) or IL-10 in combination with Matrix Metallopeptidase 9 (MMP9). Such a macrophage may be for use in treatment of an inflammatory c...
|
|
WO/2024/077159A1 |
The present disclosure provides for efficient ex vivo processes for generating B cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or mo...
|
|
WO/2024/050296A3 |
Clonal hematopoiesis is an age-related condition caused by somatic mutations that give a hematopoietic stem cell a clonal selective advantage. While clonal hematopoiesis is a benign condition, individuals affected by it have an increased...
|
|
WO/2024/075675A1 |
The present invention relates to: a stem cell population derived from human milk tooth dental pulp, the stem cell population being characterized in that at least 90% of the stem cell population is CD117-negative, CD73-positive, CD90-posi...
|
|
WO/2024/071109A1 |
The purpose of the present invention is to simplify a cell culture device. The present invention relates to a cell culture device (100) for culturing cells, the cell culture device being equipped with: a culture tank (1) for pooling a cu...
|
|
WO/2024/066919A1 |
Disclosed herein are a method for differentiating a stem cell into a caudal serotonergic neuron, a complete culture medium, and use thereof. Specifically, a small molecule compound is added to form a new culture medium, so that human plu...
|
|
WO/2024/071923A1 |
According to an aspect of the technology disclosed in the present application, the present invention relates to a cell line in which exosomes loaded with FAF1 protein are stably expressed, and relates to: a cell line, which can produce, ...
|
|
WO/2024/067888A1 |
Provided is a varicella zoster vaccine. Specifically, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a granulin component. The granulin component comprises a nanogranulin protei...
|
|
WO/2024/068760A1 |
This invention relates to methods of making immunoresponsive cells, immunoresponsive cells thereof, pharmaceutical compositions, kits, uses thereof and methods of treatment. In particular, there is provided a method of making an immunore...
|
|
WO/2024/071918A1 |
The present invention relates to a composition for manufacturing a cell film, containing a solution of acrylamide, bis-acrylamide, sodium acrylate, and TEMED in distilled water, a method for manufacturing a cell film, a cell film, and a ...
|
|
WO/2024/070382A1 |
The present invention provides: novel fine particles that include miRNA associated with NK cell activation and that are derived from a culture supernatant of stem cells derived from dental pulp or a culture supernatant of stem cells deri...
|
|
WO/2024/067389A1 |
The present application belongs to the technical field of biomedicine. More specifically, the present application relates to a kit for detecting whether a subject suffers from multiple sclerosis (MS). Furthermore, the present application...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/068648A1 |
Provided herein is a cell culture serum free medium for culturing cells in-vitro, and methods of using the cell culture serum free medium.
|
|
WO/2024/066026A1 |
Provided is a chimeric antigen receptor targeting IL13Rα2, comprising: (1) an optimized anti-IL13Rα2 scFv sequence; (2) an optimized hinge region/spacer region; (3) a transmembrane region (TM); (4) a CD28 costimulatory domain and a 4-1...
|
|
WO/2024/065892A1 |
Provided is use of a reagent for detecting an eosinophil, an eosinophil and a cytoplasm content thereof, and a lipid metabolite hydroxy docosahexaenoic acid, which belongs to the technical field of medical treatment and medicines. Provid...
|
